Verona Pharma to Present More Phase 3 ENHANCE COPD Analyses at ERS 2024

Verona Pharma plc announced its upcoming presentations at the European Respiratory Society (ERS) International Congress 2024, showcasing additional analyses from its successful Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine). Ohtuvayre is a first-in-class, selective, dual inhibitor of PDE3 and PDE4, offering both bronchodilator and non-steroidal anti-inflammatory effects. This novel inhaled therapy marks a significant advancement in the maintenance treatment of chronic obstructive pulmonary disease (COPD), being the first of its kind in over two decades.

The analyses to be presented will cover the therapy's efficacy and safety in various patient subgroups, including those with and without chronic bronchitis and European patients. Additionally, a pooled analysis will focus on patient-reported outcomes and Ohtuvayre's impact on reducing cough and sputum production. These findings underline Ohtuvayre's potential to benefit a diverse group of COPD patients.

Dr. Jadwiga Wedzicha, Professor of Respiratory Medicine at the National Heart and Lung Institute, Imperial College London, expressed enthusiasm about Ohtuvayre's non-steroidal anti-inflammatory effects and its promising impact on COPD. This sentiment is echoed by other experts involved in the study, who will also present their findings at the congress.

The detailed presentations include:

1. Oral Presentation 2780: Discussing the improvement in lung function and the reduction in moderate/severe exacerbation rates in COPD patients, irrespective of their chronic bronchitis history. This will be presented by Dr. Jadwiga Wedzicha.

2. Poster 2991: A pooled analysis from the ENHANCE trials, revealing improvements in COPD symptoms and quality of life. Dr. Alexander Mathioudakis of the University of Manchester will present this poster.

3. Poster 2995: Focusing on the efficacy and safety of Ohtuvayre in European patients with moderate to severe COPD. This analysis will be presented by Dr. Frits M.E. Franssen from Maastricht University Medical Center.

4. Poster 2997: Highlighting how Ohtuvayre improved symptoms and reduced exacerbation rates in patients with significant cough and sputum production. This presentation will be led by Dr. Victor Kim from Lewis Katz School of Medicine at Temple University.

Ohtuvayre represents a significant leap forward in COPD treatment, combining bronchodilator and anti-inflammatory effects in a single molecule. Verona Pharma's Phase 3 ENHANCE program demonstrated that the therapy met its primary endpoints, showing statistically significant and clinically meaningful improvements in lung function. Furthermore, a fixed-dose combination of ensifentrine and glycopyrrolate is currently under development for COPD maintenance treatment.

Verona Pharma is dedicated to developing and commercializing innovative therapies for chronic respiratory diseases with substantial unmet medical needs. Ohtuvayre, their first commercial product, also shows potential for treating non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma, and other respiratory conditions. The company remains committed to advancing respiratory medicine, as highlighted by their participation in the upcoming ERS congress and ongoing research efforts.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!